C Diff Drug Development

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).

The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application

Join Acurx Pharmaceuticals' Executive Chairman, Robert Deluccia today at 12:00 PM as he discusses the Company's development of Ibezapolstat for the potential treatment of #CDiff. https://t.co/I6ffQbrRiC— Antimicrobials Working Group (@AWG_News) September 7, 2022

.@gianluca1aniro: Alternatives of FMT include defined microbial consortia such as RBX2660 and SER-109 that have shown durable engraftment and good safety profile @esnm_eu #GMFHCoverage pic.twitter.com/I2zOzscgLB— GutMicrobiota Health (@GMFHx) September 6, 2022

By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...

Seres Therapeutics Announces Completion of Rolling Bla Submission to FDA for Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection.Seres Therapeutics Inc - Anticipated Product Launch in First Half of 2023.

The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application

* Immuron approved to commence clinical study in c.difficile infection (cdi)

The FDA's #VRBPAC will meet on September 22 to review data supporting the biologics license application (BLA) for @Rebiotix's RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent #CDiff after antibiotic treatment. https://t.co/GClrIVBPna— MTIG (@MTIG_News) August 22, 2022

Four novel vaccine candidates developed by a University of Guelph chemist have been recently recognized by the World Health Organization (WHO) for potential use in treating what medical experts call a…

In a recent report, the World Health Organization recognized four vaccine candidates developed by U of G prof Mario Monteiro and his research team

An FDA advisory committee will meet on September 22, 2022 to decide whether to approve a biologics license application (BLA) for Ferring’s recurrent C difficile biotherapeutic, RBX2660.

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB...

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019, unde

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Background: Clostridium difficile infection (CDI) has been widely reported in human and animals around the world over the past few decades. The high relapse rate and increasing drug resistance of CDI make the discovery of new agents against C. difficile fairly urgent. This study …

Kefir, a fermented beverage made from kefir grains, has gained immense popularity around the world due to its potential health-promoting properties. Kefir beverages are both marketed commerciall...

Scientists have created a probiotic to restore bile salt metabolism found in the gastrointestinal tract, to counter the onset and effects of Clostridium Difficile Infection (CDI).

Clostridioides difficile infection is a global health threat and remains the primary cause of hospital-acquired infections worldwide. The burgeoning incidence and severity of infections coupled with high rates of recurrence have created an urgent need for novel therapeutics. Here, we report a novel …

Summary clinical trial report, “Clostridioides difficile Infections (Clostridium difficile Associated Disease) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" provides an overview of Clostridioides difficile Infections (Clostridium difficile Associated Disease) Clinical trials scenario.New York, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Clostridioides difficile Infe

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Seres Therapeutics (MCRB) is trading 16% higher after the company on Wednesday said it expects to complete SER-109, its experimental oral microbiome therapeutic to reduce C

By Connor Hart Seres Therapeutics Inc. shares were almost 10% higher Wednesday afternoon after positive research results but below-expected earnings. The...

[SER-109: oral microbiome therapy for recurrent Clostridioides difficile infections : SER-109 versus Placebo in the Treatment of Adults with Recurrent Clostridium Difficile Infection (ECOSPOR III)]

Recently, a worrying acceleration of the emergence of antibiotic-resistant bacteria has been reported. The increase in antibiotic-associated diseases, such as Clostridioides difficile infection (CDI), has promoted research on new treatments that could be more effective and less aggressive for …

Dr Feuerstadt discusses data with 4 emerging microbiota-based live biotherapeutics for treatment of rCDI: RBX2660, SER-109, CP101, and VE303.

By Joe Hoppe Destiny Pharma PLC said Tuesday that a study of its Clostridioides difficile preventative treatment showed positive results. The London-listed...

The biotech is making final preparations to take NTCD-M3, a new antibiotic treatment for CDI, into phase III clinical trials